---
title: "Berkshire Hathaway: No plans to acquire a railway company at this time"
description: "Berkshire Hathaway: No plans to acquire a railway company at this time"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/254486726.md"
published_at: "2025-08-25T16:56:36.000Z"
---

# Berkshire Hathaway: No plans to acquire a railway company at this time

Berkshire Hathaway: No plans to acquire a railway company at this time

### Related Stocks

- [BRK.B.US - Berkshire Hathaway B](https://longbridge.com/en/quote/BRK.B.US.md)
- [BRK.A.US - Berkshire Hathaway](https://longbridge.com/en/quote/BRK.A.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| US expected to add Alibaba and other to list of firms allegedly aiding China's military, sources say | The Trump administration is set to add Alibaba and other companies to a list of firms allegedly supporting China's milit | [Link](https://longbridge.com/en/news/275904637.md) |
| Wall St Week Ahead-Walmart, economic data await investors confronting AI 'whack-a-mole' | U.S. stock investors are bracing for volatility due to AI disruption fears, with Walmart's earnings and key economic dat | [Link](https://longbridge.com/en/news/275888654.md) |
| GLOBALFOUNDRIES's Options Frenzy: What You Need to Know | Investors are taking a bearish stance on GLOBALFOUNDRIES (NASDAQ:GFS), with 58% of recent options trades being bearish.  | [Link](https://longbridge.com/en/news/275793224.md) |
| BUZZ-Street View: Hilton poised for AI gains, premium travel demand rises | Hilton Worldwide Holdingsexceeded fourth-quarter profit estimates due to strong premium travel demand, but forecasts 202 | [Link](https://longbridge.com/en/news/275777213.md) |
| AbbVie Advances New Toxin-Based Therapy in Ventral Hernia Trial: What Investors Should Watch | AbbVie (ABBV) is conducting a Phase 2 clinical trial for AGN-151607-DP, a botulinum toxin-based therapy aimed at improvi | [Link](https://longbridge.com/en/news/275926867.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.